IGF-I deficiency, longevity and cancer protection of patients with Laron syndrome

被引：45
|
作者：
Laron, Zvi [1 ]
Kauli, Rivka [1 ]
Lapkina, Lena [2 ]
Werner, Haim [2 ]
机构：
[1] Schneider Childrens Med Ctr, Endocrinol & Diabet Res Unit, Petah Tiqwa, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Dept Human Mol Genet & Biochem, Tel Aviv, Israel
来源：
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH | 2017年 / 772卷
基金：
以色列科学基金会;
关键词：
GROWTH-FACTOR-I; HORMONE RECEPTOR GENE; FAMILIAL DWARFISM; TREATED PATIENTS; INSENSITIVITY SYNDROME; PITUITARY DWARFISM; BODY-COMPOSITION; MOLECULAR-BASIS; FACTOR (IGF)-I; ADULT PATIENTS;
D O I：
10.1016/j.mrrev.2016.08.002
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Laron syndrome (LS) is a unique model of congenital IGF-I deficiency. It is characterized by dwarfism and obesity, and is caused by deletion or mutations of the growth hormone receptor (GH-R) gene. It is hypothesized that LS is an old disease originating in Indonesia and that the mutated gene spread to South Asia, the Middle East, the Mediterranean region and South America. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码：123 / 133
页数：11
相关论文
共 50 条
  • [11] Sequential measurements of IGF-I serum concentrations in adolescents with Laron syndrome treated with recombinant human IGF-I (rhIGF-I)
    Breil, Thomas
    Kneppo, Carotin
    Bettendorf, Markus
    Mueller, Hermann L.
    Kapelari, Klaus
    Schnabel, Dirk
    Woelfle, Joachim
    [J]. JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2018, 31 (08): : 895 - 902
  • [12] MODULATION OF INSULIN-LIKE GROWTH FACTOR-I (IGF-I) BINDING-SITES ON ERYTHROCYTES BY IGF-I TREATMENT IN PATIENTS WITH LARON SYNDROME (LS)
    ESHET, R
    KLINGER, B
    SILBERGELD, A
    LARON, Z
    [J]. REGULATORY PEPTIDES, 1993, 48 (1-2) : 233 - 239
  • [13] Long-term IGF-I treatment of children with Laron syndrome increases adiposity
    Laron, Z
    Ginsberg, S
    Lilos, P
    Arbiv, M
    Vaisman, N
    [J]. GROWTH HORMONE & IGF RESEARCH, 2006, 16 (01) : 61 - 64
  • [14] The GH/IGF-I axis and longevity
    Holzenberger, M
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2004, 151 : S23 - S27
  • [15] IGF-I Signaling and Effects on Longevity
    Holzenberger, Martin
    [J]. EARLY NUTRITION: IMPACT ON SHORT- AND LONG-TERM HEALTH, 2011, 68 : 237 - 249
  • [16] IGF-I treatment of patients with Laron syndrome suppresses serum thrombopoietin levels but does not affect serum erythropoietin
    Shevah, Orit
    Yacobovich, Joanne
    Zoldan, Meira
    Tamary, Hannah
    Laron, Zvi
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (01) : 64 - 64
  • [17] Head circumference in untreated and IGF-I treated patients with Laron syndrome Comparison with untreated and hGH-treated children with isolated growth hormone deficiency
    Laron, Zvi
    Iluz, Moshe
    Kauli, Rivka
    [J]. GROWTH HORMONE & IGF RESEARCH, 2012, 22 (02) : 49 - 52
  • [18] Hearing loss in patients with Laron syndrome (primary growth hormone insensitivity) is reversed by early IGF-I replacement therapy
    Attias, Joseph
    Negeris, Benny
    Zarhi, Omer
    Laron, Zvi
    [J]. HORMONE RESEARCH, 2008, 70 : 84 - 84
  • [19] Control of aging and longevity by IGF-I signaling
    Yang, J
    Anzo, M
    Cohen, P
    [J]. EXPERIMENTAL GERONTOLOGY, 2005, 40 (11) : 867 - 872
  • [20] Development of hyperandrogenism during treatment with insulin-like growth factor-I (IGF-I) in female patients with Laron syndrome
    Klinger, B
    Anin, S
    Silbergeld, A
    Eshet, R
    Laron, Z
    [J]. CLINICAL ENDOCRINOLOGY, 1998, 48 (01) : 81 - 87
12345